Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
Release Notes Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: CND002
MIFTS: 49

Conduct Disorder

Categories: Mental diseases
Data Licensing
For inquiries, contact:
[email protected]
Genes Tissues Related diseases Publications Drugs
Sources

Aliases & Classifications for Conduct Disorder

About this section

MalaCards integrated aliases for Conduct Disorder:

Name: Conduct Disorder 11 75 53 43 14 16 71

Classifications:

MalaCards categories:
Anatomical: Mental diseases
See all MalaCards categories (disease lists)
ICD10: 31


External Ids:

Disease Ontology 11 DOID:12995
ICD9CM 34 312.9
MeSH 43 D019955
NCIt 49 C89329
SNOMED-CT 68 430909002
ICD10 31 F91 F91.9
UMLS 71 C0149654
Sources

Summaries for Conduct Disorder

About this section

Disease Ontology: 11 A specific developmental disorder marked by a pattern of repetitive behavior wherein the rights of others or social norms are violated.

MalaCards based summary: Conduct Disorder is related to impulse control disorder and brunner syndrome. An important gene associated with Conduct Disorder is MAOA (Monoamine Oxidase A), and among its related pathways/superpathways are Transmission across Chemical Synapses and Neuroscience. The drugs Oxcarbazepine and Aripiprazole have been mentioned in the context of this disorder. Affiliated tissues include brain, cingulate cortex and amygdala, and related phenotypes are nervous system and homeostasis/metabolism

Wikipedia: 75 Conduct disorder (CD) is a mental disorder diagnosed in childhood or adolescence that presents itself... more...
Sources

Related Diseases for Conduct Disorder

About this section

Diseases related to Conduct Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 212)
# Related Disease Score Top Affiliating Genes
1 impulse control disorder 31.7 SLC6A4 SLC6A3 MAOA DRD4 DRD2 COMT
2 brunner syndrome 31.5 TPH1 SLC6A4 MAOA COMT
3 oppositional defiant disorder 31.2 SLC6A4 SLC6A3 OXTR OXT MAOA GABRA2
4 personality disorder 30.6 TPH1 SLC6A4 SLC6A3 OXTR MAOA DRD4
5 cannabis abuse 30.5 SLC6A4 DRD4 DRD2 COMT
6 tic disorder 30.5 SLC6A4 SLC6A3 MAOA DRD4 DRD2 COMT
7 bipolar i disorder 30.4 SLC6A4 DRD2 COMT
8 borderline personality disorder 30.4 TPH1 SLC6A4 SLC6A3 OXTR MAOA DRD2
9 agoraphobia 30.4 SLC6A4 MAOA COMT
10 antisocial personality disorder 30.4 SLC6A4 SLC6A3 OXTR OXT MAOA GABRA2
11 acute stress disorder 30.4 SLC6A4 POMC OXT
12 pervasive developmental disorder 30.3 SLC6A4 RBFOX1 OXTR OXT DRD2
13 alcohol use disorder 30.2 SLC6A4 SLC6A3 POMC MAOA GABRA2 DRD4
14 obsessive-compulsive personality disorder 30.2 SLC6A4 COMT
15 post-traumatic stress disorder 30.2 SLC6A4 SLC6A3 POMC OXTR OXT MAOA
16 asperger syndrome 30.2 SLC6A4 OXTR OXT COMT
17 adjustment disorder 30.1 SLC6A4 POMC OXT
18 schizoaffective disorder 30.1 SLC6A4 DRD4 DRD2 COMT
19 opiate dependence 30.1 SLC6A4 SLC6A3 POMC DRD4 DRD2 COMT
20 narcissistic personality disorder 30.1 OXT MAOA
21 attention deficit-hyperactivity disorder 30.0 TPH1 SLC6A4 SLC6A3 RBFOX1 POMC OXTR
22 separation anxiety disorder 30.0 SLC6A4 OXTR OXT MAOA DRD4 COMT
23 phobia, specific 30.0 SLC6A4 OXT MAOA COMT
24 autism spectrum disorder 30.0 SLC6A4 SLC6A3 RBFOX1 OXTR OXT MAOA
25 bipolar disorder 30.0 TPH1 SLC6A4 SLC6A3 RBFOX1 MAOA GABRA2
26 major depressive disorder 30.0 TPH1 SLC6A4 SLC6A3 POMC OXT MAOA
27 gilles de la tourette syndrome 29.9 SLC6A4 SLC6A3 MAOA DRD4 DRD2 DBH
28 intermittent explosive disorder 29.9 SLC6A4 OXT MAOA DRD2 COMT
29 alexithymia 29.9 SLC6A4 OXTR OXT DRD2 COMT
30 autism 29.9 SLC6A4 SLC6A3 RBFOX1 OXTR OXT MAOA
31 drug dependence 29.9 SLC6A4 SLC6A3 POMC MAOA GABRA2 DRD4
32 dysthymic disorder 29.8 SLC6A4 SLC6A3 POMC OXT MAOA DRD4
33 anxiety 29.8 TPH1 SLC6A4 SLC6A3 POMC OXTR OXT
34 panic disorder 29.8 TPH1 SLC6A4 SLC6A3 POMC MAOA DRD4
35 postpartum depression 29.7 SLC6A4 POMC OXTR OXT MAOA COMT
36 bulimia nervosa 29.7 SLC6A4 SLC6A3 OXT MAOA DRD4 DRD2
37 substance abuse 29.6 SLC6A4 SLC6A3 POMC OXT MAOA GABRA2
38 social phobia 29.6 SLC6A4 SLC6A3 POMC OXTR OXT MAOA
39 neurotic disorder 29.6 SLC6A4 POMC OXT MAOA COMT
40 substance dependence 29.5 TPH1 SLC6A4 SLC6A3 POMC MAOA GABRA2
41 alcohol dependence 29.5 TPH1 SLC6A4 SLC6A3 POMC MAOA GABRA2
42 psychotic disorder 29.5 TPH1 SLC6A4 SLC6A3 OXTR OXT MAOA
43 generalized anxiety disorder 29.4 TPH1 SLC6A4 POMC OXT MAOA DRD2
44 disease of mental health 29.4 SLC6A4 SLC6A3 POMC OXTR OXT MAOA
45 mood disorder 29.4 TPH1 SLC6A4 SLC6A3 POMC OXT MAOA
46 eating disorder 29.4 SLC6A4 SLC6A3 POMC OXTR OXT DRD2
47 tobacco addiction 29.3 TPH1 SLC6A4 SLC6A3 MAOA GABRA2 DRD4
48 melancholia 29.3 TPH1 SLC6A4 POMC OXT MAOA COMT
49 parkinson disease, late-onset 29.2 TPH1 SLC6A4 SLC6A3 MAOA DRD4 DRD2
50 obsessive-compulsive disorder 29.2 TPH1 SLC6A4 SLC6A3 POMC OXTR OXT

Comorbidity relations with Conduct Disorder via Phenotypic Disease Network (PDN):


Acute Cystitis Alzheimer Disease, Familial, 1
Deficiency Anemia Schizophreniform Disorder

Graphical network of the top 20 diseases related to Conduct Disorder:



Diseases related to Conduct Disorder
Sources

Symptoms & Phenotypes for Conduct Disorder

About this section

GenomeRNAi Phenotypes related to Conduct Disorder according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.2 ALDH2 C1QTNF7 C5orf15 COMT DBH DRD2
2 no effect GR00402-S-2 10.2 ALDH2 C1QTNF7 C5orf15 COMT DBH DRD2

MGI Mouse Phenotypes related to Conduct Disorder:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 10.24 ALDH2 COMT DBH DRD2 DRD4 GABRA2
2 homeostasis/metabolism MP:0005376 10.22 ALDH2 C1QTNF7 COMT DBH DRD2 DRD4
3 endocrine/exocrine gland MP:0005379 9.96 ALDH2 COMT DBH DRD2 OXT OXTR
4 cardiovascular system MP:0005385 9.9 ALDH2 COMT DBH DRD2 GABRA2 MAOA
5 behavior/neurological MP:0005386 9.86 ALDH2 COMT DBH DRD2 DRD4 GABRA2
6 integument MP:0010771 9.36 ALDH2 DBH DRD2 GABRA2 NTSR2 OXT
Sources

Drugs & Therapeutics for Conduct Disorder

About this section

Drugs for Conduct Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 37)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oxcarbazepine Approved Phase 4 28721-07-5 34312
2
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
3
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
4
Dextroamphetamine Approved, Illicit, Investigational Phase 4 51-64-9, 300-62-9 5826 3007
5
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
6
Dopamine Approved Phase 4 62-31-7, 51-61-6 681
7
Methylphenidate Approved, Investigational Phase 4 113-45-1 4158
8 Antidepressive Agents Phase 4
9 Dopamine agonists Phase 4
10 Sodium Channel Blockers Phase 4
11 Anticonvulsants Phase 4
12 Diuretics, Potassium Sparing Phase 4
13 Serotonin Receptor Agonists Phase 4
14 Serotonin 5-HT1 Receptor Agonists Phase 4
15 Adrenergic Agents Phase 4
16 Adderall Phase 4
17 Sympathomimetics Phase 4
18 Antipsychotic Agents Phase 4
19 Neurotransmitter Agents Phase 4
20 Dopamine Antagonists Phase 4
21 Dopamine Agents Phase 4
22 Psychotropic Drugs Phase 4
23 Central Nervous System Stimulants Phase 4
24 Dopamine Uptake Inhibitors Phase 4
25
Serotonin Investigational, Nutraceutical Phase 4 50-67-9 5202
26
Ethanol Approved Phase 2, Phase 3 64-17-5 702
27
Lithium carbonate Approved Phase 3 554-13-2
28
Ziprasidone Approved Phase 2 146939-27-7 60854
29 Pharmaceutical Solutions Phase 2
30
Brexpiprazole Approved, Investigational Phase 1 913611-97-9 11978813
31
Benzocaine Approved, Investigational 1994-09-7, 94-09-7 2337
32
Tannic acid Approved 1401-55-4 16129878 16129778
33
Glutamic acid Approved, Nutraceutical 56-86-0 33032
34 Omega 3 Fatty Acid
35 Hormones
36 Complement System Proteins
37 Nitrox

Interventional clinical trials:

(show top 50) (show all 79)
# Name Status NCT ID Phase Drugs
1 Early Primary Prevention of Conduct Problems Completed NCT00051714 Phase 4
2 A Multi-center, Randomized, Double-blind, Cross-over, Placebo-controlled Clinical Trial to Evaluate Efficacy and Safety of Oxcarbazepine p.o. (300-1200 mg/Day) as Adjuvant Therapy for Impulsivity and Aggressive Behavior in Conduct Disorders in Adolescents Completed NCT00154362 Phase 4 Oxcarbazepine
3 Open Label Trial of Aripiprazole in the Treatment of CD in Adolescents Completed NCT00250705 Phase 4 Aripiprazole
4 Double-Blind, Placebo-Controlled Trial of Flexible Dose Divalproex Sodium Adjunctive to Stimulant Treatment for Aggressive Children With Attention-Deficit Hyperactivity Disorder Completed NCT00228046 Phase 4 Divalproex Sodium;Methylphenidate;Dextroamphetamine;Mixed Amphetamine Salts
5 Brain Indices of Stimulant Treatment in Drug-Naive Youth at Risk for Substance Use Disorder Recruiting NCT04170738 Phase 4 Adderall
6 The Assessment of Efficacy and Tolerability of Methylphenidate vs. Risperidone in the Treatment of Children and Adolescents With ADHD and Disruptive Disorders Terminated NCT02063945 Phase 4 Methylphenidate;Risperidone
7 The Safety And Efficacy Of Risperidone Versus Placebo In Conduct Disorder and Other Disruptive Behavior Disorders In Mild, Moderate And Borderline Mentally Retarded Children Aged 5 To 12 Years Completed NCT00266552 Phase 3 risperidone
8 The Safety And Efficacy Of Risperidone Versus Placebo In Conduct Disorder In Mild, Moderate And Borderline Mentally Retarded Children Aged 5 To 12 Years Completed NCT00250354 Phase 3 Risperidone oral solution
9 Long-Term Lithium for Aggressive Conduct Disorder Completed NCT00000385 Phase 3 Lithium;Placebo
10 Effects of Risperidone on Cognitive-Motor Performance and Motor Movements in Chronically Medicated Children Completed NCT00399698 Phase 3 Risperdal
11 Cognitive Behavioral Interventions That Target Personality Risk for Substance Abuse and Mental Illness: Delivery by Educational Professionals Completed NCT00776685 Phase 2, Phase 3
12 RCT of an Animal-Assisted Intervention With Adjudicated Youth Completed NCT01594606 Phase 3
13 A New School-based Drug Prevention Programme for Teenagers: Interventions That Target Personality Risk for Substance Abuse and Mental Illness Completed NCT00344474 Phase 2, Phase 3
14 Ziprasidone for Severe Conduct and Other Disruptive Behavior Disorders in Children and Adolescents - a Placebo Controlled, Randomized, Double Blind Clinical Trial Completed NCT00676429 Phase 2 Ziprasidone Hydrochloride;Placebo
15 A Randomized, Multicenter, Parallel Group, Dose-Ranging Study to Evaluate the Safety and Tolerability of SPN-810 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD) and Persistent Serious Conduct Problems Completed NCT00626236 Phase 2 SPN-810
16 Preventive Intervention for Mexican American Adolescents Completed NCT00051727 Phase 2
17 Home-based Behavioral Therapy (HBT): Psychosocial Intervention Project for Early Adolescents With Pre- or Early Substance Use Disorder: Phase II Completed NCT00280228 Phase 2
18 Evaluation of a Group-based, Cognitive-behavioural Intervention With Former Child Soldiers and Other War-affected Children in the Democratic Republic of Congo: A Randomised Controlled Trial. Completed NCT01494831 Phase 2
19 Intervening Early With Neglected Children: Key Childhood Outcomes Active, not recruiting NCT02093052 Phase 1, Phase 2
20 Investigating the Impact of Methylphenidate on Neural Response in Disruptive Behavioral Disorder Withdrawn NCT02247986 Phase 1, Phase 2 Methylphenidate Hydrochloride
21 Treatment of Youth Comorbid Conduct Problems and Depression Unknown status NCT01267773 Phase 1
22 A Phase 1, Single-dose, Sequential Cohort, Nonrandomized Crossover Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Oral Brexpiprazole in Children (6 to< 13 Years Old) With Central Nervous System Disorders Completed NCT03292848 Phase 1 Brexpiprazole
23 A Clinic-based Program for Families of Depressed Mothers Completed NCT00149812 Phase 1
24 Investigating the Relationship Between Children With ADHD and Conduct Disorder and Their Parents in Reduction of Symptoms Unknown status NCT03691389
25 Real-time fMRI for the Treatment of Aggressive Behavior in Adolescents (Part of EU-MATRICS: Multidisciplinary Approaches to Translational Research) Unknown status NCT02563145
26 Prevention and Reduction of Alcohol and Drug Problems in a Clinical Psychiatric Youth Population Unknown status NCT01595568
27 Parent Management Training to Prevent Oppositional Defiant and Conduct Disorders in Preschool Children Unknown status NCT00189189
28 PREVENTING CONDUCT DISORDER AMONG CHILDREN IN THE CHILD WELFARE SYSTEM Completed NCT03329625
29 A Nutritional and Social Skills Intervention on Conduct Disorder and Hyperactivity Completed NCT00819429
30 A Multiple Biomarker Approach to Investigating Psychosocial Intervention Treatment Response in Justice-Involved Youth With Conduct Disorder Completed NCT02998073
31 Mentalization-based Training for Adolescents With Conduct Disorder (MBT-CD): A Feasibility and Pilot Study Completed NCT02988453
32 Group-based Parenting Program "Incredible Years" to Reduce Child Conduct Disorder Symptoms in Families With Child Protection and Other Family Support Services in Finland Completed NCT03239990
33 Development, Piloting and Evaluation of a Phone-Delivered Psychological Intervention (t-CETA) for Syrian Refugee Children in Lebanon: Phase II Completed NCT03887312
34 Evaluating the Effectiveness of Technology Assisted School Mental Health Program to Improve Socio-emotional Wellbeing of School Going Children in Public Schools of Rural Pakistan: A Cluster Randomized Controlled Trial (cRCT) Completed NCT04091633
35 Virtual Reality to Improve Social Perspective Taking in Youth With Disruptive Behavior Disorders Completed NCT03927612
36 Online vs Staff Delivery: Child & Family Outcomes, Value Analysis, Satisfaction Completed NCT02121431
37 Evaluating an Online Parenting Support System Disseminated by Pediatric Practices Completed NCT02064452
38 Investigation of Psychophysiological Response to Aversive Stimuli Over Time With Omega-3 Completed NCT03749824
39 Family Groups to Reduce Youth Behavioral Difficulties Completed NCT00404911
40 Investigation of Psychophysiological Correlation of Aggression and Response to Aversive Stimuli Completed NCT03725371
41 Effectiveness of an Anti-bullying Intervention for Adolescent Perpetrators: Using Tools Measuring Brain Function and Structure, Cognition and Behavior. Completed NCT02670876
42 Can a Physical Activity Program Implemented at a Therapeutic School Promote Emotional Regulation and School Success in Socially and Emotionally Vulnerable Children? Completed NCT02766101
43 Evaluation of the Effectiveness of a Combined Mindful Parenting and Parent Training Program on Children With Disruptive Behavioral Problems and Their Families Completed NCT03796663
44 Enhancing Long-Term Outcome in Child Behavior Disorders Completed NCT00820001
45 Investigating the Neuro-Cognitive Underpinnings of the Emotional Dysfunction Linked to Childhood Behavioral Disturbance Completed NCT00104039
46 Study of Cognition and Control in Youths Completed NCT03393390
47 Arousal-Biofeedback for the Treatment of Aggressive Behavior in Children and Adolescents (Part of EC FP7 Project Aggressotype: Aggression Subtyping for Improved Insight and Treatment Innovation in Psychiatric Disorders) Completed NCT02485587
48 The Effectiveness of Parent-Child Interaction Therapy (PCIT) in Treating Behavior Problems in Young Children Completed NCT01085305
49 Preventing Health Disparities in Hispanic Youth Completed NCT02318745
50 Reliability and Validity of the MINI International Neuropsychiatric Interview for Children and Adolescents (MINI-KID) Completed NCT00579267

Search NIH Clinical Center for Conduct Disorder

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Lithium
Lithium Aspartate
Lithium Carbonate
lithium citrate

Cochrane evidence based reviews: conduct disorder

Sources

Genetic Tests for Conduct Disorder

About this section
Sources

Anatomical Context for Conduct Disorder

About this section

Organs/tissues related to Conduct Disorder:

MalaCards : Brain, Cingulate Cortex, Amygdala, Prefrontal Cortex, Cortex, Temporal Lobe, Eye
Sources

Publications for Conduct Disorder

About this section

Articles related to Conduct Disorder:

(show top 50) (show all 4234)
# Title Authors PMID Year
1
Variation in the catechol-O-methyltransferase Val 158 Met polymorphism associated with conduct disorder and ADHD symptoms, among adolescent male delinquents. 53 62
19997043 2010
2
Associations of the DRD2 TaqIA polymorphism with impulsivity and substance use: preliminary results from a clinical sample of adolescents. 53 62
19344737 2009
3
Genetic risk for conduct disorder symptom subtypes in an ADHD sample: specificity to aggressive symptoms. 53 62
19465875 2009
4
Monoamine oxidase A and childhood adversity as risk factors for conduct disorder in females. 53 62
18752729 2009
5
Is fetal brain monoamine oxidase inhibition the missing link between maternal smoking and conduct disorders? 53 62
18592036 2008
6
Case-control and within-family tests for an association between conduct disorder and DAT1. 53 62
18197081 2008
7
Testing for gene x environment interaction effects in attention deficit hyperactivity disorder and associated antisocial behavior. 53 62
17579368 2008
8
Adolescent conduct disorder and interpersonal callousness as predictors of psychopathy in young adults. 53 62
17658978 2007
9
A gene x gene interaction between DRD2 and DRD4 is associated with conduct disorder and antisocial behavior in males. 53 62
17587443 2007
10
COMT Val108/158Met gene variant, birth weight, and conduct disorder in children with ADHD. 53 62
17075359 2006
11
MAOA and the "cycle of violence:" childhood abuse and neglect, MAOA genotype, and risk for violent and antisocial behavior. 53 62
16814261 2006
12
Interaction between MAO-A genotype and maltreatment in the risk for conduct disorder: failure to confirm in adolescent patients. 53 62
16741202 2006
13
Gene-environment interaction in hyperkinetic conduct disorder (HD + CD) as indicated by season of birth variations in dopamine receptor (DRD4) gene polymorphism. 53 62
15288435 2004
14
Childhood adversity, monoamine oxidase a genotype, and risk for conduct disorder. 53 62
15237086 2004
15
Associations of the serotonin transporter promoter polymorphism with aggressivity, attention deficit, and conduct disorder in an adoptee population. 53 62
12658617 2003
16
Two dopamine genes related to reports of childhood retrospective inattention and conduct disorder symptoms. 53 62
11443528 2001
17
Dopamine D2 receptor gene (DRD2) is associated with alcoholism with conduct disorder. 53 62
11236830 2001
18
A dinucleotide repeat polymorphism at the gene for monoamine oxidase A and measures of aggressiveness. 53 62
8771218 1995
19
Serum dopamine beta hydroxylase and maltreatment in psychiatrically hospitalized boys. 53 62
7583738 1995
20
Genetic factors in substance abuse based on studies of Tourette syndrome and ADHD probands and relatives. I. Drug abuse. 53 62
8082550 1994
21
Low dopamine-beta-hydroxylase: a biological sequela of abuse and neglect? 53 62
1771204 1991
22
Shared genetic influences between depression and conduct disorder in children and adolescents: A systematic review. 62
36356897 2023
23
Proposed Specifiers for Conduct Disorder (PSCD): Factor Structure and Validation of the Self-Report Version in Community and Forensic Samples of Portuguese Youth. 62
34523369 2023
24
Development of an Empathy Rating Scale for Young Children. 62
34459262 2023
25
Investigating Direct and Indirect Genetic Effects in Attention-Deficit/Hyperactivity Disorder Using Parent-Offspring Trios. 62
35933166 2023
26
Adolescent substance use and high school noncompletion: exploring the nature of the relationship using a discordant twin design. 62
35815374 2023
27
Longitudinal relations between impaired executive function and symptoms of psychiatric disorders in childhood. 62
35478317 2022
28
Some critical comments on the paper titled "Some critical considerations in applying the construct of psychopathy to research and classification of childhood disruptive behavior disorders". 62
36328895 2022
29
Does Conduct, Oppositional Defiant, and Panic Disorder Symptoms Associate with Suicidal Ideations Among African American Adolescents? 62
36439662 2022
30
Antipsychotics in the Management of Disruptive Behavior Disorders in Children and Adolescents: An Update and Critical Review. 62
36359338 2022
31
Key demographic and mental disorder diagnostic differences between Australian First Nations and non-First Nations clinic-referred children and adolescents assessed in a culturally appropriate and safe way. 62
34875892 2022
32
Effects of Computer-Assisted Social Skills Training in Children With Disruptive Behavior Disorders: A Randomized Controlled Trial. 62
35398192 2022
33
[Sensory regulation disorders in child psychiatry]. 62
36443135 2022
34
Trends in the prevalence of conduct disorder from 1990 to 2019: Findings from the Global Burden of Disease Study 2019. 62
36265191 2022
35
Mentalization-based treatment for adolescents with conduct disorder (MBT-CD): a feasibility study. 62
36434148 2022
36
Inventory of Callous-Unemotional Traits (ICU) Factor Structure and Measurement Invariance in an Adolescent Multinational Sample. 62
36450005 2022
37
[Course of School Absenteeism 1.5-3 Years After Initial Evaluation: Symptoms, Psychosocial Functioning, and Help-Seeking Behavior]. 62
35748577 2022
38
Circadian cortisol secretion in adolescent girls with conduct disorder. 62
36462295 2022
39
The association between treated psychiatric and neurodevelopmental disorders and out-of-home care among Finnish children born in 1997. 62
34101021 2022
40
Parental Antisocial and Psychopathic Traits Influence Adolescent Psychopathology. 62
33949245 2022
41
Telepsychiatry Use Before and During the COVID-19 Pandemic Among Children Enrolled in Medicaid. 62
36444530 2022
42
Effects of comorbidity on executive functions among children with ADHD, finding trends. 62
36395527 2022
43
Associations of toddler mechanical/distress feeding problems with psychopathology symptoms five years later. 62
35048380 2022
44
Signal in the noise: Altered brain activation among adolescent alcohol users detected via the analysis of intra-individual variability1. 62
36102952 2022
45
ADHD symptoms and diurnal cortisol in adolescents: The importance of comorbidities. 62
36462296 2022
46
Prenatal smoking, alcohol and caffeine exposure and offspring externalizing disorders: a systematic review and meta-analysis. 62
35385887 2022
47
Long-term methylphenidate use for children and adolescents with attention deficit hyperactivity disorder and risk for depression, conduct disorder, and psychotic disorder: a nationwide longitudinal cohort study in South Korea. 62
36221129 2022
48
Probable Risperidone-Associated Acute Pancreatitis in a Child with ADHD. 62
36339277 2022
49
Where Should Psychopathic Traits Be Placed in a Diagnostic Framework? Evidence for a Grandiose-Manipulative Specifier for ODD. 62
35420392 2022
50
Using Digital Technology to Overcome Racial Disparities in Child and Adolescent Psychiatry. 62
35358663 2022
Sources

Variations for Conduct Disorder

About this section
Sources

Expression for Conduct Disorder

About this section
Search GEO for disease gene expression data for Conduct Disorder.
Sources

Pathways for Conduct Disorder

About this section

Pathways related to Conduct Disorder according to GeneCards Suite gene sharing:

(show all 14)
# Super pathways Score Top Affiliating Genes
1
Transmission across Chemical Synapses 66
Show member pathways
 12.88 SLC6A4 SLC6A3 MAOA GABRA2 COMT ALDH2
2
Neuroscience 3
12.36 TPH1 POMC DBH COMT
3
Amino acid metabolism 74
Show member pathways
 11.67 TPH1 MAOA DBH
4
Monoamine transport 74
Show member pathways
 11.19 SLC6A4 SLC6A3 MAOA DBH
5
Biogenic amine synthesis 74
Show member pathways
 11.16 TPH1 SLC6A3 MAOA DBH COMT
6
Selective Serotonin Reuptake Inhibitor Pathway, Pharmacodynamics 60
10.99 MAOA SLC6A4 TPH1
7
Antipsychotics Pathway (Metabolic Side Effects), Pharmacodynamics 60
10.84 POMC DRD2
8
Tyrosine metabolism p.1 (dopamine) 22
10.75 MAOA DBH COMT
9
Neurotransmitter clearance 66
Show member pathways
 10.75 SLC6A4 SLC6A3 MAOA COMT ALDH2
10
Dopamine metabolism 74
10.61 MAOA COMT
11
Methylphenidate Pathway, Pharmacodynamics 60
Show member pathways
 10.53 SLC6A4 SLC6A3 MAOA DRD4 DRD2 DBH
12
Vasopressin-like receptors 66
Show member pathways
 10.52 OXTR OXT
13
Propranolol Pathway, Pharmacokinetics 60
10.39 MAOA ALDH2
14
dopamine degradation 61
10.1 MAOA COMT
Sources

GO Terms for Conduct Disorder

About this section

Cellular components related to Conduct Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005887 10.28 DRD2 DRD4 GABRA2 NTSR2 OXTR SLC6A3
2 plasma membrane GO:0005886 10.28 DRD2 DRD4 GABRA2 NTSR2 OXTR SLC6A3
3 membrane GO:0016020 10.16 C5orf15 COMT DBH DRD2 DRD4 GABRA2
4 membrane GO:0016021 10.16 C5orf15 COMT DBH DRD2 DRD4 GABRA2
5 postsynaptic membrane GO:0045211 9.62 SLC6A4 SLC6A3 GABRA2 DRD2
6 obsolete integral component of presynaptic membrane GO:0099056 9.33 SLC6A4 SLC6A3 DRD2
7 obsolete integral component of postsynaptic membrane GO:0099055 8.8 SLC6A4 SLC6A3 DRD2

Biological processes related to Conduct Disorder according to GeneCards Suite gene sharing:

(show all 29)
# Name GO ID Score Top Affiliating Genes
1 memory GO:0007613 10.08 SLC6A4 OXTR OXT DBH
2 neurotransmitter transport GO:0006836 10.06 SLC6A4 SLC6A3 GABRA2
3 social behavior GO:0035176 10.01 SLC6A4 OXTR OXT DRD4
4 sleep GO:0030431 9.94 OXTR OXT
5 regulation of dopamine metabolic process GO:0042053 9.93 SLC6A3 DRD4
6 dopamine metabolic process GO:0042417 9.93 DRD4 DRD2 COMT
7 drinking behavior GO:0042756 9.92 OXT DRD2
8 monoamine transport GO:0015844 9.92 SLC6A4 SLC6A3
9 positive regulation of uterine smooth muscle contraction GO:0070474 9.91 OXTR OXT
10 neurotransmitter catabolic process GO:0042135 9.91 MAOA COMT
11 adenohypophysis development GO:0021984 9.9 SLC6A3 DRD2
12 hyaloid vascular plexus regression GO:1990384 9.89 DRD2 SLC6A3
13 dopamine uptake involved in synaptic transmission GO:0051583 9.88 SLC6A3 DRD2
14 fear response GO:0042596 9.87 DRD4 DBH
15 negative regulation of gastric acid secretion GO:0060455 9.86 OXTR OXT
16 response to cocaine GO:0042220 9.86 SLC6A3 OXTR OXT DRD2
17 positive regulation of penile erection GO:0060406 9.85 OXTR OXT
18 maternal behavior GO:0042711 9.85 OXTR OXT DBH
19 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.84 DRD4 DRD2
20 positive regulation of norepinephrine secretion GO:0010701 9.83 OXTR OXT
21 response to histamine GO:0034776 9.81 DRD2 DRD4
22 positive regulation of dopamine uptake involved in synaptic transmission GO:0051586 9.8 DRD2 DRD4
23 behavioral response to ethanol GO:0048149 9.8 DBH DRD2 DRD4
24 response to amphetamine GO:0001975 9.65 OXTR OXT DRD4 DRD2 DBH
25 regulation of biological quality GO:0065008 9.64 DRD4 DRD2
26 catecholamine metabolic process GO:0006584 9.63 MAOA COMT
27 sperm ejaculation GO:0042713 9.63 SLC6A4 OXTR OXT
28 regulation of digestive system process GO:0044058 9.43 OXTR OXT
29 dopamine catabolic process GO:0042420 9.23 SLC6A3 MAOA DBH COMT

Molecular functions related to Conduct Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 monoamine transmembrane transporter activity GO:0008504 9.56 SLC6A4 SLC6A3
2 dopamine neurotransmitter receptor activity GO:0004952 9.33 DRD4 DRD2
3 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.26 DRD4 DRD2
4 dopamine binding GO:0035240 9.1 SLC6A3 DRD4 DRD2
Sources

Sources for Conduct Disorder

About this section
2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....